An interventional study of Mobile chest radiography for tuberculosis screening in Tuberculosis (TB), Tuberculosis Infection, Latent and HIV (Human Immunodeficiency Virus), sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Columbia University · Not applicable, Interventional, and Screening
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a community-based tuberculosis (TB) screening strategy for migrant populations in New York City. The screening intervention integrates mobile ultra-portable digital chest radiography with artificial intelligence-assisted image interpretation, tuberculosis symptom assessment, latent tuberculosis infection testing, and HIV testing. Participants with concerning screening findings are referred for appropriate clinical evaluation. The study will evaluate the feasibility, acceptability, and effectiveness of this integrated screening strategy for improving early identification of active pulmonary tuberculosis and linkage to care in community settings.
Tuberculosis (TB) remains a major public health challenge in the United States, with increasing numbers of reported cases in recent years. Delayed diagnosis contributes to ongoing transmission and poorer clinical outcomes, particularly among populations facing barriers to healthcare access. Migrant populations in New York City experience a disproportionately high burden of TB infection and disease, highlighting the need for innovative community-based screening strategies.
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a novel community-based TB screening strategy. The intervention combines mobile ultra-portable digital chest radiography, artificial intelligence-assisted image interpretation, tuberculosis symptom assessment, latent tuberculosis infection testing, and HIV testing to provide rapid, front-loaded screening while minimizing loss to follow-up. Participants with concerning screening findings are referred for appropriate clinical evaluation according to standard clinical practice.
The study will evaluate the feasibility, acceptability, and effectiveness of this integrated screening strategy for improving early identification of active pulmonary tuberculosis, facilitating linkage to care, and informing future community-based TB screening programs. The study will also provide information on TB and latent TB infection prevalence among migrant populations and the implementation of mobile AI-assisted screening in an urban U.S. setting.
199 studies on the registry are indexed under Latent Tuberculosis; 48 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 300 across 110 interventional studies indexed under Latent Tuberculosis.
Browse Latent Tuberculosis studies →Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.
Of its 180 completed or terminated interventional studies of FDA-regulated products, 148 (82%) have results posted.
Compared within Latent Tuberculosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo the SPOT-TB screening strategy, which includes symptom screening, chest radiography interpreted using AI software, HIV testing, and collection of sputum for confirmatory microbiologic testing when indicated.
Diagnostic Test: Mobile chest radiography for tuberculosis screening
The diagnostic screening includes a digital chest x-ray (includes AI software to interpret x-rays), optional lung ultrasound, oral swab for HIV testing, and a blood draw for TB testing.
Completion of Appropriate Clinical Referrals
Proportion of participants who complete recommended diagnostic evaluations and clinical referrals, stratified by tuberculosis risk screening group.
Time frame: Up to 12 weeks post-visit
Plan to share: Yes — De-identified individual participant data underlying the results reported in publications will be shared in accordance with the study's Data Management and Sharing Plan and applicable institutional and regulatory requirements.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for May 2027, 9 months after the start.
Of 30 interventional studies with no phase under Latent Tuberculosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 9 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → May 2028, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.